Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 463K
2: EX-10.2 Material Contract HTML 32K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 18K
12: R1 Cover Page HTML 74K
13: R2 Condensed Consolidated Balance Sheets HTML 129K
14: R3 Condensed Consolidated Statements of Operations HTML 100K
15: R4 Condensed Consolidated Statements of Comprehensive HTML 45K
Loss
16: R5 Condensed Consolidated Statements of Stockholders? HTML 57K
Equity
17: R6 Condensed Consolidated Statements of Cash Flows HTML 117K
18: R7 Description of Business and Basis of Presentation HTML 24K
19: R8 Summary of Significant Accounting Policies HTML 30K
20: R9 Other Financial Statement Information HTML 97K
21: R10 Commitments and Contingencies HTML 37K
22: R11 Capital Stock HTML 23K
23: R12 Equity Incentive Plans HTML 42K
24: R13 Net Loss Per Share HTML 28K
25: R14 Summary of Significant Accounting Policies HTML 42K
(Policies)
26: R15 Other Financial Statement Information (Tables) HTML 110K
27: R16 Commitments and Contingencies (Tables) HTML 33K
28: R17 Equity Incentive Plans (Tables) HTML 45K
29: R18 Net Loss Per Share (Tables) HTML 28K
30: R19 Summary of Significant Accounting Policies - HTML 19K
Additional Information (Detail)
31: R20 Other Financial Statement Information - HTML 46K
Available-for-Sale Securities (Details)
32: R21 Other Financial Statement Information - Additional HTML 34K
Information (Detail)
33: R22 Other Financial Statement Information - HTML 35K
Contractual Maturities of Marketable Securities
(Details)
34: R23 Other Financial Statement Information - Schedule HTML 28K
of Inventory (Detail)
35: R24 Other Financial Statement Information - Schedule HTML 34K
of Accrued Compensation and Related Benefits
(Detail)
36: R25 Other Financial Statement Information - Schedule HTML 41K
of Accrued Expense And Other Current Liabilities
(Detail)
37: R26 Other Financial Statement Information - Schedule HTML 25K
of Changes in the Reserve for Product Warranties
(Detail)
38: R27 Other Financial Statement Information - Revenue HTML 21K
Recognition (Details)
39: R28 Other Financial Statement Information - Schedule HTML 29K
of Revenue by Source (Detail)
40: R29 Other Financial Statement Information - Schedule HTML 33K
of Revenue by Geographic Region (Details)
41: R30 Commitments and Contingencies - Additional HTML 24K
Information (Detail)
42: R31 Commitments and Contingencies - Summary of HTML 39K
Company's Operating Lease Liabilities (Detail)
43: R32 Commitments and Contingencies - Summary of HTML 22K
Additional Information Related to Operating Leases
(Detail)
44: R33 Capital Stock - Additional Information (Detail) HTML 30K
45: R34 Equity Incentive Plans - Additional Information HTML 29K
(Detail)
46: R35 Equity Incentive Plans - Recorded Stock-Based HTML 27K
Compensation Expense in the Condensed Consolidated
Statement of Operations (Details)
47: R36 Equity Incentive Plans - Summary of RSU Activity HTML 41K
(Detail)
48: R37 Equity Incentive Plans - Summary of Company's HTML 39K
Stock Option Activity (Details)
49: R38 Net Loss Per Share - Shares of Common Stock HTML 33K
Equivalents Were Excluded From The Computation of
Diluted Net Loss Per Share (Details)
52: XML IDEA XML File -- Filing Summary XML 91K
50: XML XBRL Instance -- txg-20220331_htm XML 827K
51: EXCEL IDEA Workbook of Financial Reports XLSX 53K
8: EX-101.CAL XBRL Calculations -- txg-20220331_cal XML 178K
9: EX-101.DEF XBRL Definitions -- txg-20220331_def XML 243K
10: EX-101.LAB XBRL Labels -- txg-20220331_lab XML 1.02M
11: EX-101.PRE XBRL Presentations -- txg-20220331_pre XML 555K
7: EX-101.SCH XBRL Schema -- txg-20220331 XSD 96K
53: JSON XBRL Instance as JSON Data -- MetaLinks 277± 400K
54: ZIP XBRL Zipped Folder -- 0001770787-22-000029-xbrl Zip 330K
1. I have reviewed this Quarterly Report on Form 10-Q of 10x Genomics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the
registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
